Cargando…
Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trial
INTRODUCTION: Gallbladder cancer (GBC) is an aggressive type of digestive system cancer with a dismal outcome. Given the lack of effective treatment options, the disease rapidly reoccurs and 5-year survival rate is <5%. Our team previously found that a significant percentage of GBC tissues harbou...
Autores principales: | Yang, Mao, Zhao, Yuhao, Li, Yongsheng, Cui, Xuya, Liu, Fatao, Wu, Wenguang, Wang, Xu-An, Li, Maolan, Liu, Yun, Liu, Yingbin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980349/ https://www.ncbi.nlm.nih.gov/pubmed/36854604 http://dx.doi.org/10.1136/bmjopen-2022-061892 |
Ejemplares similares
-
Overview of current targeted therapy in gallbladder cancer
por: Song, Xiaoling, et al.
Publicado: (2020) -
Second-Line Treatment of NSCLC—The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms
por: Köhler, Jens
Publicado: (2017) -
A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer
por: Modjtahedi, Helmout, et al.
Publicado: (2014) -
A new solvate of afatinib, a specific inhibitor of the ErbB family of tyrosine kinases
por: Zeller, Matthias, et al.
Publicado: (2017) -
Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder
por: Liu, Fatao, et al.
Publicado: (2021)